UK markets close in 1 hour 5 minutes

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6000+0.0044 (+0.74%)
As of 10:17AM EST. Market open.

Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway SE
Suite 1900
Atlanta, GA 30339
United States
678 392 3419
https://www.inhibikase.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees6

Key executives

NameTitlePayExercisedYear born
Dr. Milton H. Werner Ph.D.CEO, Pres & Director472.11kN/A1963
Mr. Joseph Frattaroli CPAChief Financial Officer375kN/A1962
Dr. Roger RushHead of Preclinical ResearchN/AN/AN/A
Dr. Surendra SinghHead of Chemistry, Manufacturing & ControlsN/AN/AN/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.Interim Chief Medical Officer & Science AdvisorN/AN/AN/A
Dan WilliamsControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Corporate governance

Inhibikase Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.